Related Experiment Video
Updated: Jun 7, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
[Glucagon-like peptide-1: a cardiological perspective].
Mikkel Elvekjaer1, Thomas Engstrøm, Jan Skov Jensen
1Kobenhavns Universitet, Biomedicinsk Institut, Denmark.
Ugeskrift for Laeger
|October 22, 2010
Summary
Glucagon-like peptide-1 (GLP-1) analogs show promising cardiac benefits beyond diabetes control. Studies suggest these agents can protect heart muscle from damage and improve heart function, warranting further clinical investigation.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) and its analogs are known for their glucose-lowering and metabolic effects.
- Emerging evidence suggests direct cardiovascular actions of GLP-1 analogs.
- These actions extend beyond their established antidiabetic properties.
Purpose of the Study:
- To investigate the direct effects of glucagon-like peptide-1 (GLP-1) analogs on the heart and circulatory system.
- To explore the potential of GLP-1 analogs in mitigating cardiac damage and improving cardiac function.
Main Methods:
- Review of experimental evidence and small patient trials.
- Analysis of GLP-1 analog effects on vasodilation, myocardial infarction outcomes, and left ventricular contractility.
Main Results:
- GLP-1 analogs demonstrate vasodilatory effects.
- Evidence suggests a reduction in heart muscle loss following myocardial infarction.
- Potential for increased contractility in weakened left ventricles was observed.
- Small patient trials offer preliminary support for cardiac effects.
Conclusions:
- GLP-1 analogs possess direct cardioprotective properties.
- The myocardium-saving effect after coronary occlusion and reperfusion is a key area for clinical testing.
- Further clinical trials are warranted to validate these cardiovascular benefits.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...